Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Non-cash Items (2022 - 2025)

Silence Therapeutics' Non-cash Items history spans 4 years, with the latest figure at $6.0 million for Q4 2025.

  • For Q4 2025, Non-cash Items rose 109.05% year-over-year to $6.0 million; the TTM value through Dec 2025 reached $6.0 million, up 109.05%, while the annual FY2025 figure was $6.0 million, 79.38% down from the prior year.
  • Non-cash Items for Q4 2025 was $6.0 million at Silence Therapeutics, up from $4.0 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $6.0 million in Q4 2025 and bottomed at $2.2 million in Q4 2022.
  • The 4-year median for Non-cash Items is $3.4 million (2025), against an average of $3.6 million.
  • The largest annual shift saw Non-cash Items decreased 4.47% in 2024 before it skyrocketed 109.05% in 2025.
  • A 4-year view of Non-cash Items shows it stood at $2.2 million in 2022, then surged by 35.56% to $3.0 million in 2023, then decreased by 4.47% to $2.9 million in 2024, then soared by 109.05% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for SLN's Non-cash Items are $6.0 million (Q4 2025), $4.0 million (Q3 2025), and $3.7 million (Q2 2025).